Application of eriochin in preparation of medicine for preventing and treating GBM crescent nephritis and proteinuria of GBM crescent nephritis

By using Forskolin to inhibit harmful pathways and upregulate podocyte gene expression, the side effects and limited efficacy of existing drugs in the treatment of anti-GBM crescent nephritis and proteinuria are solved, and effective against GBM crescent nephritis and proteinuria is achieved. Prevention and treatment, avoiding the side effects of glucocorticoids.

CN119033763APending Publication Date: 2024-11-29NANJING GENERAL HOSPITAL NANJING MILLITARY COMMAND P L A
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411459831.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing drugs for the treatment of anti-GBM crescent nephritis and their proteinuria, such as glucocorticoids, have huge side effects, and have limited efficacy on different types of podocyte injuries, and have failed to effectively target specific mechanisms.

Method used

Forskolin is used as a drug to inhibit the STAT3, p53, NFκB, FAK and TGF-β pathways, and simultaneously upregulate the essential genes of podocytes WT1, SYNPO and VEGFA, which are used to prepare anti-GBM crescent nephritis and its proteinuria.

Benefits of technology

Forskolin has significant efficacy in preventing NTS-induced proteinuria and podocyte damage, which can replace glucocorticoid treatment, avoid its side effects, and show comparable efficacy to glucocorticoids in mouse models, while reducing podocyte dedifferentiation and injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033763A_ABST
    Figure CN119033763A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of kidney pathology and pharmacology, and particularly relates to application of Forskolin in preparation of a medicine for preventing and treating GBM crescent nephritis and proteinuria of the GBM crescent nephritis. The NTS-induced podocyte injury is characterized by WT1 down-regulation, and Forskolin can directly up-regulate WT1, so that Forskolin is prompted to be capable of antagonizing podocyte dedifferentiation so as to relieve the injury; as an activator of adenylate cyclase, the Forskolin can inhibit STAT3, p53, NF [kappa] B, FAK and TGF-beta pathways in mechanism, and meanwhile, can up-regulate essential genes WT1, SYNPO and VEGFA of podocyte; forskolin can replace glucocorticoid to treat podocyte damage and proteinuria, the Forskolin can protect podocytes by directly inhibiting harmful pathways and related genes, and meanwhile, expression of essential genes of the podocytes is enhanced without being damaged, so that the Forskolin has the efficacy equivalent to that of the glucocorticoid in an NTS treated mouse; forskolin can replace glucocorticoid to treat anti-GBM glomerulonephritis so as to avoid side effects of the anti-GBM glomerulonephritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of nephrology and pharmacology, and specifically relates to the application of forskolin in preparing medicines for preventing and treating anti-GBM crescentic nephritis and proteinuria. Background Art

[0002] Podocyte injury can lead to podocyte loss, which in turn leads to various glomerular lesions and end-stage renal disease. Podocyte injury often causes destruction of the glomerular filtration barrier, leading to proteinuria, tubular cell injury, tubular interstitial fibrosis, inflammation, edema, and systemic damage to the body. Therefore, controlling podocyte injury and proteinuria is crucial for the treatment of glomerular diseases.

[0003] Podocyte injury can be induced by different molecular mechanisms, depending on the type of injury or disease. For example, podocyte injury caused by single gene mutations has different molecular pathogenesis compared with podocyte injury caused by toxins, metabolic stimulation and immune abnormalities. Among various types of podocyte injury, podocyte injury induced by nephrotoxic serum is characterized by anti-GBM IgG deposition and involvement of glomerular crescent formation. Nephrotoxic serum (NTS)-treated mice are an animal model of anti-GBM glomerulonephritis. Currently, the mechanism of podocyte injury and proteinuria in NTS mice is unclear.

[0004] In theory, the design of podocyte protection and anti-proteinuria regimens should target the specific mechanisms of podocyte injury. However, the mechanisms of various types of podocyte injury are far from being fully understood, and there are no drugs that act on the specific mechanisms of a given podocyte injury. Most of the drugs currently used to treat podocyte injury and proteinuria are repeatedly used, including steroids, immunosuppressants, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. They exert their therapeutic effects through broad, complex, and nonspecific mechanisms involving hemodynamics, immune effects, and multiple cells in the kidney. Glucocorticoids have been shown to act directly on podocytes to exert anti-proteinuric effects, but glucocorticoids have huge side effects. In our study, we noticed that high-dose methylprednisolone pulses were effective in reducing excessive NTS-induced massive proteinuria. Unfortunately, this therapy led to severe mortality in mice; moreover, proteinuria resumed once treatment was stopped.

[0005] In addition to NTS-induced podocyte injury, other types of podocyte injury should also verify the efficacy of Forskolin. A study showed that Forskolin had a certain effect on alleviating doxorubicin-induced proteinuria in mice, but the degree of relief was much smaller than that in the current NTS model. This is understandable because the mechanism and genes involved in doxorubicin-induced podocyte injury are different from those in the NTS model. Summary of the invention

[0006] In order to solve the defects and shortcomings of glucocorticoids in treating anti-GBM crescentic nephritis and provide a new possibility for the application of Forskolin in treating anti-GBM crescentic nephritis, the present invention discloses the application of Forskolin in preparing a drug for preventing and treating anti-GBM crescentic nephritis and proteinuria thereof.

[0007] To achieve the above object, the technical solution of the present invention is as follows:

[0008] The invention provides application of forskolin in preparing medicine for preventing and treating anti-GBM crescentic nephritis and proteinuria thereof.

[0009] Furthermore, the forskolin inhibits STAT3, p53, NFκB, FAK and TGF-β pathways, while upregulating podocyte essential genes WT1, SYNPO and VEGFA to prevent and treat anti-GBM crescentic nephritis and proteinuria.

[0010] Furthermore, the dosage form of the drug includes capsules, tablets, oral liquid preparations, microcapsule preparations or injections.

[0011] Furthermore, the effective dose of forskolin is 5ug / kg-20ug / kg.

[0012] Furthermore, the capsule, tablet, oral liquid preparation, microcapsule preparation or injection also includes excipients acceptable in the medical field.

[0013] The beneficial effects of the present invention are:

[0014] Forskolin has a strong effect in preventing NTS-induced proteinuria, podocyte foot process regression and glomerular crescent formation. Glucocorticoids have been shown to act directly on podocytes to exert anti-proteinuric effects. Therefore, the efficacy of Forskolin and methylprednisolone on severe podocyte injury induced by excessive NTS was compared. It was found that they had similar effects on proteinuria. This finding suggests that Forskolin can replace glucocorticoids to treat podocyte injury and proteinuria, while taking into account that glucocorticoids have huge side effects, while Forskolin is a natural supplement with limited side effects. In the present invention, due to the availability of podocyte gene expression and CMAP database, Forskolin was determined to be very effective for podocyte injury in the NTS model. Since NTS-induced podocyte injury is characterized by WT1 downregulation, and Forskolin can directly upregulate WT1, it is suggested that Forskolin can antagonize podocyte dedifferentiation and thus reduce injury. As an activator of adenylate cyclase, forskolin can inhibit STAT3, p53, NFκB, FAK and TGF-β pathways, and upregulate podocyte essential genes WT1, SYNPO and VEGFA. Forskolin can replace glucocorticoids to treat podocyte injury and proteinuria.

[0015] In summary, forskolin protects podocytes by directly inhibiting harmful pathways and related genes while enhancing the expression of essential podocyte genes without damage, thus having an efficacy comparable to that of glucocorticoids in NTS-treated mice. Forskolin could replace glucocorticoids in the treatment of anti-GBM glomerulonephritis to avoid the side effects of the latter. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a phenotypic study of Forskolin on the NTS mouse model, including: A, treatment regimen; B, mouse urine albumin level shown by silver staining; C, ELISA method to determine the mouse urine albumin / creatinine ratio (ACR) (**p<0.05 compared with the control; ##p<0.05 compared with NTS mice); D, electron microscopic photos of podocytes; E, PAS staining of mouse glomeruli; F, immunofluorescence staining of WT1 in mouse glomeruli; G / H, immunohistochemical staining and quantitative graph of P-CREB1 in mouse podocytes; I, anti-goat IgG immunofluorescence staining of mouse glomeruli;

[0017] Figure 2 To compare the efficacy of Forskolin and methylprednisolone in treating severe proteinuria in mice induced by high-dose NTS;

[0018] Figure 3The effect of Forskolin on human podocytes cultured in vitro: A, CCK8 test results after podocytes were treated with NTS and Forskolin; B / C, Phalloidin staining results and quantitative diagram of podocytes;

[0019] Figure 4 To detect the effects of Forskolin on various pathway molecules in podocytes in vitro by WB and qPCR: A. Extract the immunoblotting results of podocyte proteins after experimental treatment; B. Quantify the immunoblotting results; C. Extract the qPCR results of podocytes after experimental treatment. DETAILED DESCRIPTION

[0020] The present invention will be further explained below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the following specific embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0021] Example 1

[0022] Model building and analysis

[0023] C57 / B6 mice, 8-10 weeks old, weighing about 25 g, were purchased from Jiangsu Jicui Pharmaceutical Technology Co., Ltd., China. One batch of mice was divided into four groups: 1) untreated control group, 2) Forskolin control group, 3) NTS group, and 4) NTS+Forskolin group. The NTS group and NTS+Forskolin group were injected with 5 ml / kg NTS in the tail vein once, and the untreated control group and Forskolin control group were injected with the same dose of normal saline. The Forskolin control group and NTS+Forskolin group were injected with FSK at 5 μg / kg intraperitoneally every day, and the untreated control group and NTS group were injected with the same amount of normal saline every day ( Figure 1 A). Another batch of mice was divided into four groups: 1) NTS group, 2) NTS+Forskolin group, 3) NTS+methylprednisolone group, and 4) NTS+methylprednisolone shock group. According to the commonly used dose in the literature, NTS was injected into the tail vein, and FSK or methylprednisolone was injected intraperitoneally every day, with the doses of 5μg / kg and 2.5μg / kg, respectively. During shock treatment, the clinical methylprednisolone shock dose was used, and methylprednisolone was injected 20μg / kg every day.

[0024] Urine was collected daily. At the time of sampling, mice were anesthetized by isoflurane inhalation, and then ketamine / thiazide hydrochloride solution (ketamine dose, 100 mg / kg; thiazide, 10 mg / kg body weight) was intraperitoneally injected for complete anesthesia. After blood was collected from the orbital sinus, PBS buffer was perfused through the left ventricle. The kidney was cut into two halves, one half was embedded in OCT, and then quickly frozen in liquid nitrogen for immunofluorescence staining, and the other half was fixed with 4% paraformaldehyde and embedded in paraffin for PAS staining. To detect proteinuria, 1 ul of mouse urine sample was mixed with 7.5 μl RIPA buffer and 1.5 μl loading buffer (6X), and the sample was loaded into a 10% polyacrylamide gel for electrophoresis, and then the gel was silver stained using Fast silver Stain Kit (Beyotime, Shanghai). The urinary albumin and creatinine levels of mice were measured using Albuwell M and creatinine matching kits (Exocell Inc.). After paraffin embedding, a 4 μm thick section was cut and stained with PAS reagent. At the same time, we used electron microscopy for observation. A piece of renal cortical tissue was fixed in 3.75% glutaraldehyde cold solution for 4 hours, washed 5 times in 0.1M phosphate buffer (pH7.5), fixed in 2% nitrogen tetroxide for 2 hours, dehydrated in gradient acetone and ethanol, and then embedded in epoxy resin (SPI Inc., Westchester, PA), and ultrathin sections (80-90 nm) were obtained, stained with uranyl acetate and lead citrate, and examined and photographed with a Hitachi 7500 transmission electron microscope (Hitachi Co., Japan). The renal cortical tissue was embedded in OCT, quickly frozen in liquid nitrogen, and 5 μm frozen tissue sections were cut using a cryostat (Leica CM 3050S, Germany). The tissue sections were blocked with bovine serum albumin and incubated with anti-WT1 (Abcam) antibody, then the sections were incubated with FITC-conjugated anti-goat secondary antibody AlexaFluor 488-labeled goat anti-rabbit IgG (H+L) (Bioworld) and mounted using Fluoromount G (Sigma). The slides were examined using a Zeiss LSM710 confocal microscope.

[0025] Mice in the NTS group initially had mild proteinuria, but proteinuria increased significantly in the following days. In contrast, mice in the NTS+FSK group maintained low levels for several days ( Figure 1 B, 1C). EM ultrastructural examination showed that the foot processes in the NTS group were significantly reduced, which is a characteristic of podocyte injury, while the lesions in the NTS+Forskolin group were significantly alleviated ( Figure 1D). Since the NTS model also has the characteristic of glomerular crescent formation, we performed statistical analysis on the number of glomerular crescents and found that the glomerular crescent formation was obvious in the NTS group, while the glomerular crescent formation was reduced in the NTS+Forskolin group ( Figure 1 E). To determine whether the massive proteinuria in the NTS group was caused by podocyte loss, we performed WT1 immunofluorescence staining on the kidneys and found that their podocyte numbers were not reduced ( Figure 1 F), indicating that NTS did not cause podocyte death and loss. To determine whether Forskolin indeed affected the activity of PKA in mouse podocytes, we used immunohistochemical staining to detect the downstream effector of PKA, p-CREB, and found that, as expected, Forskolin prevented the NTS-induced downregulation of p-CREB ( Figure 1 G, 1H). To exclude the possibility that the differences between the NTS group and the NTS+FSK group might be due to different anti-GBM IgG deposition in the glomeruli, we performed IgG immunofluorescence staining and found that the IgG intensity of the NTS group and the NTS+FSK group was indistinguishable ( Figure 1 I), anti-goat IgG staining showed the deposition of goat anti-GBM IgG in mouse glomeruli (control group, n=2; FSK group, n=2; NTS group, n=5; NTS+FSK group, n=5. *P<0.05, the difference was statistically significant. **P<0.01; ***P<0.001****P<0.0001).

[0026] To further confirm the protective effect of Forskolin on podocytes, we compared the protective effects of Forskolin and glucocorticoid (methylprednisolone, MP) on podocytes of severely damaged mice treated with excessive NTS. Figure 2 As shown. Silver staining shows the urine albumin level 24 hours after injection of high-dose NTS (day 1) and on days 5, 10, and 15 after treatment with Forskolin (FSK), methylprednisolone (MP), and methylprednisolone shock (MP shock). N = 6 per group. The efficacy was compared by the percentage of urine albumin reduction in each mouse in the three groups. 24 hours after injection of excessive NTS, mice developed massive proteinuria ( Figure 2), and then Forskolin, MP and MP pulse administration were given respectively. On the 5th day of treatment, the proteinuria levels of the three groups of mice were basically unchanged compared with the proteinuria levels on the 1st day. On the 10th day, the proteinuria in the FSK group and the MP group was significantly reduced. Unfortunately, in the MP group with pulse administration, half of the mice died; however, the proteinuria attenuation in the remaining half of the mice was most significant. To avoid further death in the MP shock group, 3 mice were switched to regular MP doses from the 11th day. On the 15th day, proteinuria in the FSK group and the MP group was further reduced, and the degree of relief was generally similar. Unexpectedly, mice switched from the shock dose to conventional MP treatment showed similar levels of proteinuria to the other two groups, indicating that the relief effect of the shock treatment on proteinuria is reversible.

[0027] Example 2

[0028] Drug efficacy experiment

[0029] In order to explore the protective mechanism of Forskolin on podocytes, we established an in vitro culture model of podocytes and divided the cells into four groups: 1) untreated control group, 2) 5uM Forskolin group, 3) 10% NTS group, and 4) 10% NTS + 5uM Forskolin group. HPC-S cells were differentiated for 5 days, and then the medium of each group was changed. The control group was replaced with conventional culture medium, the 5uM Forskolin group was replaced with culture medium containing 5uM FSK, the 10% NTS group was replaced with culture medium containing 10% NTS, and the 10% NTS + 5uM Forskolin group was replaced with culture medium containing 5uM FSK and 10% NTS. The cell viability was determined using the CCK8 (Beyotime, Shanghai, China) kit according to the manufacturer's instructions. To detect whether there is an effect on the cytoskeleton, after the treatment, the cells were fixed with 4% PFA for 10 min at room temperature, washed 3 times with PBS, permeabilized with 0.5% Triton-X for 5 min, washed 3 times with PBS, incubated with 100 nM Phalloidin solution for 30 min in the dark at room temperature, washed with PBS, and stained with 20 μl DAPI for 5 min. After the treatment, the podocytes were washed with cold PBS, and then lysed with RIPA buffer containing protease inhibitors and phosphatase inhibitors. The cell lysate was centrifuged at 12000g for 15 min at 4°C. The supernatant was transferred to a new centrifuge tube, and the protein concentration was determined using a BCA protein kit (Bio-Rad). The samples were mixed with the loading buffer, boiled for 5 min, and electrophoresed with SDS-PAGE (10%) to transfer the proteins to a PVDF membrane. The cells were incubated at room temperature for 1 h in a blocking solution containing 5% milk in a TBST solution (20 mM Tris-HCl, PH 7.14, 150 mM NaCl, 0.1% Tween-20), and then incubated with antibodies. The antibodies used in the present invention include: anti-STAT3 (Proteintech), anti-phospho-STAT3 (Abcam), anti-p53 (Beyotime), anti-phospho-p53 (Beyotime), anti-p65 (Cell Signaling Technology), anti-phospho-p65 (Cell Signaling Technology), anti-fak (Bioworld), anti-phospho-fak (Affinity), anti-gapdh (Proteintech), anti-pai-1 (Proteintech), anti-wt1 (Abcam), and anti-cortacn (Proteintech).Total RNA from cultured human podocytes was extracted using Trizol (Invitrogen) and reverse transcribed using a Takara kit. RNA samples were used for gene expression quantification using a qRT-PCR kit (Takara). We used SYBR Green dye in qPCR. Thermal cycling conditions were 95°C / 30 s, and 40 cycles of 95°C / 5 s and 60°C / 30 s were performed on an Applied Biosystems 7900 Real-time PCR system. Threshold cycle (CT) values ​​were measured, and the relative abundance of mRNA was calculated using the formula 2-△△CT. GAPDH rRNA was used for data normalization.

[0030] According to CCK8 experiments, it was found that NTS weakened cell viability, while Forskolin attenuated NTS-induced cell viability impairment ( Figure 3 A). In phalloidin staining, which is used to assess cytoskeletal integrity, NTS was found to greatly reduce F-actin stress fibers, indicating cytoskeletal damage in podocytes. However, in NTS+Forskolin-treated cells, Forskolin normalized F-actin stress fibers ( Figure 3 B, 3C); p < 0.05 was considered statistically significant. **p < 0.01; ***p < 0.001. These results support that NTS-induced podocyte injury is a valid in vitro model and was therefore used for mechanistic studies.

[0031] The present invention immunoblotted molecules known to be associated with podocyte injury, including STAT3, p53, NF-kappa B (p65), FAK, and PAI-1. Forskolin itself can reduce the levels of total p53 and p65 proteins and inhibit the injury pathway by downregulating their markers p-p53, p-STAT3, p-p65, p-FAK, and PAI-1 ( Figure 4 A, 4B). At the same time, the study found that Forskolin can directly upregulate WT1, a major regulatory protein of podocyte structure and function, and contactin, an essential protein of podocytes ( Figure 4 A, 4B). RT-qPCR analysis of target genes also confirmed the direct regulatory effect of Forskolin on target genes. We found that Forskolin inhibited the mRNA expression of harmful molecules (CCL2, TNF-α, IL-18, and PAI-1), while upregulated the mRNA expression of essential molecules (WT1, VCAM1, VEGFA, and SYNPO) ( Figure 4C). Combining the above in vitro model study results, there are two important findings. One is that Forskolin directly inhibited the injury pathway and upregulated the expression of essential podocyte genes independent of NTS. The other is that NTS-induced podocyte injury in mice may be mainly mediated by soluble factors in NTS samples and may be independent of anti-GBM IgG deposition.

[0032] It should be noted that the above content only illustrates the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. For ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications all fall within the protection scope of the claims of the present invention.

Claims

1. Application of forskolin in the preparation of drugs for preventing and treating anti-GBM crescentic nephritis and proteinuria.

2. The use of forskolin according to claim 1 in the preparation of a medicament for preventing and treating anti-GBM crescentic nephritis and proteinuria thereof, characterized in that: The forskolin inhibits STAT3, p53, NFκB, FAK and TGF-β pathways and simultaneously upregulates podocyte essential genes WT1, SYNPO and VEGFA to prevent and treat anti-GBM crescentic nephritis and proteinuria.

3. The use of forskolin according to claim 1 in the preparation of a medicament for preventing and treating anti-GBM crescentic nephritis and proteinuria thereof, characterized in that: The dosage form of the drug includes capsules, tablets, oral liquid preparations, microcapsule preparations or injections.

4. The use of forskolin according to claim 3 in the preparation of a medicament for preventing and treating anti-GBM crescentic nephritis and proteinuria thereof, characterized in that: The effective dosage of forskolin is 5-20 μg / kg.

5. The use of forskolin according to claim 3 in the preparation of a medicament for preventing and treating anti-GBM crescentic nephritis and proteinuria thereof, characterized in that: The capsule, tablet, oral liquid preparation, microcapsule preparation or injection also includes excipients acceptable in the medical field.

Citation Information

Cited By

  • Application of eriolaryngol in preparation of medicine for treating MASLD

    CN121221587A